Your browser is no longer supported. Please, upgrade your browser.
GILD Gilead Sciences, Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E9.22 EPS (ttm)8.79 Insider Own0.30% Shs Outstand1.31B Perf Week2.43%
Market Cap105.76B Forward P/E11.89 EPS next Y6.81 Insider Trans-21.58% Shs Float1.30B Perf Month7.79%
Income11.60B PEG- EPS next Q1.68 Inst Own79.60% Short Float1.81% Perf Quarter1.21%
Sales27.48B P/S3.85 EPS this Y-16.50% Inst Trans0.05% Short Ratio2.81 Perf Half Y10.30%
Book/sh19.02 P/B4.26 EPS next Y-21.62% ROA19.40% Target Price85.63 Perf Year13.15%
Cash/sh21.74 P/C3.73 EPS next 5Y-14.08% ROE53.40% 52W Range63.76 - 86.27 Perf YTD13.04%
Dividend2.08 P/FCF11.62 EPS past 5Y41.20% ROI31.00% 52W High-6.13% Beta1.13
Dividend %2.57% Quick Ratio3.60 Sales past 5Y29.40% Gross Margin84.80% 52W Low27.01% ATR1.63
Employees9000 Current Ratio3.70 Sales Q/Q-13.20% Oper. Margin57.80% RSI (14)70.89 Volatility1.68% 2.01%
OptionableYes Debt/Eq1.18 EPS Q/Q-17.10% Profit Margin42.20% Rel Volume0.83 Prev Close81.17
ShortableYes LT Debt/Eq1.11 EarningsFeb 06 AMC Payout22.90% Avg Volume8.38M Price80.98
Recom2.40 SMA207.01% SMA508.91% SMA20010.50% Volume6,965,975 Change-0.23%
Jan-16-18Upgrade Wells Fargo Market Perform → Outperform
Dec-20-17Downgrade Credit Suisse Outperform → Neutral
Nov-30-17Upgrade Maxim Group Hold → Buy $94
Nov-13-17Downgrade Argus Buy → Hold
Nov-08-17Reiterated Mizuho Buy $77 → $83
Oct-11-17Resumed Barclays Overweight $90
Oct-05-17Initiated Oppenheimer Perform
Oct-04-17Resumed Jefferies Hold $93
Sep-15-17Initiated RBC Capital Mkts Outperform $94
Sep-05-17Reiterated Wells Fargo Market Perform $73 → $81
Aug-31-17Upgrade Argus Hold → Buy
Aug-31-17Resumed William Blair Outperform $87
Jul-11-17Resumed Jefferies Hold
Jun-23-17Initiated Deutsche Bank Buy $79
Mar-09-17Resumed UBS Neutral $118 → $72
Feb-08-17Downgrade Citigroup Buy → Neutral
Nov-14-16Initiated Stifel Buy $100
Nov-08-16Initiated Mizuho Buy $88
Nov-02-16Reiterated RBC Capital Mkts Outperform $95 → $90
Oct-25-16Reiterated Jefferies Buy $93 → $95
Jan-19-18 05:35PM  Gilead Collaborates with Pfizer for Yescarta Combo Study Zacks
05:23PM  CVS and Gilead Sciences Hit the Casualty List GuruFocus.com
04:39PM  Which Biotech Stocks Could Surprise To The Upside On Earnings? Investor's Business Daily
12:31PM  Gilead Earnings: Don't Get Too Excited Barrons.com
09:05AM  Merck & Co.s Human Vaccines Business in 3Q17 Market Realist
07:34AM  Keytruda: Merck & Co.s Immuno-Oncology Blockbuster Drug Market Realist
06:45AM  Celgene Corporation Stock Needs More Than a Juno Acquisition to Thrive InvestorPlace
Jan-18-18 05:24PM  Healthcare: Is Celgene Going to Buy Juno Therapeutics? Motley Fool
11:24AM  Merck & Co., Inc. Stock Could Still Soar Another 10% From Here InvestorPlace
09:25AM  3 Top-Ranked Drug Stocks That Are Broker Favorites InvestorPlace
08:30AM  Kite Announces Clinical Collaboration to Evaluate Investigational Combination of Yescarta (Axicabtagene Ciloleucel) and Pfizers Utomilumab in Large B-Cell Lymphoma Business Wire
07:45AM  No Reason To Rush Into Juno Therapeutics Inc Stock After This Big Pop InvestorPlace
Jan-17-18 10:00PM  What's Juno Therapeutics Worth to Celgene? Motley Fool
06:43PM  Florida man gets prison for trading on tip about Gilead deal Reuters
01:00PM  How a Juno Takeover Could Boost Celgene Investopedia
12:53PM  Why Celgene's Rumored Acquisition Of Juno Actually Makes Sense Investor's Business Daily
11:37AM  Why Juno Therapeutics Stock Is Soaring Today Motley Fool
09:00AM  Is Celgene (CELG) Looking to Take Over Juno Therapeutics? Zacks
08:32AM  Is Gilead Sciences, Inc. a Buy in 2018? Motley Fool
08:03AM  See what the IHS Markit Score report has to say about Gilead Sciences Inc. Markit
Jan-16-18 11:51AM  Gilead: Finally an Upgrade! Barrons.com
10:45AM  Can Vertex Pharmaceuticals Report Solid 2017 Net Profit Margins? Market Realist
09:15AM  Why Vertex Pharmaceuticals Raised Its 2017 Revenue Guidance Market Realist
09:00AM  How Teva Pharmaceutical Plans to Improve Financial Profile Market Realist
08:03AM  See what the IHS Markit Score report has to say about Gilead Sciences Inc. Markit
07:40AM  Analyst Recommendations for Vertex Pharmaceuticals in January Market Realist
07:31AM  How Teva Pharmaceutical Plans to Optimize Global Generics Market Realist
Jan-15-18 11:16AM  Gilead, CVS And Two Other Stocks Down But Not Out Forbes
10:31AM  How Teva Pharmaceutical Is Realigning Organizational Structure Market Realist
09:02AM  Teva Pharmaceutical Focusing on Per Product Operating Profits Market Realist
08:02AM  See what the IHS Markit Score report has to say about Gilead Sciences Inc. Markit
07:34AM  Can Tevas Debt Repayment Plan Deleverage Its Balance Sheet? Market Realist
Jan-12-18 12:50PM  Teva to Lose 2025 Sites, Cut 14,000 Workers in Next 2 Years Market Realist
10:00AM  2017 Was a Year to Forget for Gilead Sciences, Inc., but This Year Could Be Better Motley Fool
08:03AM  See what the IHS Markit Score report has to say about Gilead Sciences Inc. Markit
06:30AM  3 Reasons Dividend-Monster Pfizer Inc. Could Explode Higher InvestorPlace
Jan-11-18 11:50AM  Mavyret May Prove a Strong Growth Driver for AbbVie Going Forward Market Realist
11:49AM  New Year, New Gilead? It's No Longer Just About Hepatitis C Barrons.com
10:33AM  What Does Tevas Recently Announced Restructuring Plan Entail? Market Realist
10:19AM  Can Biotech Keep Last Year's Momentum Alive in 2018? Zacks
09:04AM  TEVA Stock Price Rises on Generic Launch of Viread Market Realist
09:03AM  How Akcea Therapeutics Volanesorsen Performed in 3Q17 Market Realist
07:44AM  Big Pharma CEOs Speak About Impact of Tax Reform on M&A Zacks
07:34AM  Tevas Launch of Generic Version of Reyataz Boosts Stock Market Realist
07:34AM  How Ioniss Spinraza Performed in 3Q17 Market Realist
07:33AM  How Mylans Europe Segment Performed in 3Q17 Market Realist
05:29AM  Valeant Pharmaceuticals Intl Inc Stock Is Worth the Risk InvestorPlace
Jan-10-18 04:10PM  Exploring Ioniss 3Q17 Quarterly Revenue Trend Market Realist
03:05PM  How Mylans North America Segment Performed in 3Q17 Market Realist
06:00AM  Gilead's Breakout May Spark 18% Gain Investopedia
Jan-09-18 03:31PM  5 Ways Gilead Sciences Plans to Return to Growth Motley Fool
03:15PM  Gilead CEO: We still intend to invest in M&A and our pipe... CNBC Videos
10:31AM  Valeant on the Street: Analyst Recommendations in December 2017 Market Realist
09:12AM  Moody's: US pharmaceutical companies' cash holdings set to decline under new tax law Moody's
08:21AM  3 Top Healthcare Stocks to Buy in January Motley Fool
Jan-08-18 01:03PM  Tax cuts are barely priced into earnings expectations: NYSE trader Yahoo Finance Video
Jan-07-18 09:09AM  5 Biggest New Drugs of 2018 -- and How You Can Profit From Their Makers Motley Fool
Jan-05-18 07:20PM  Top 5 Biotech Stocks for 2018 Investopedia
01:17PM  [$$] Buying Micron, Gilead, Apple and Under Armour Barrons.com
08:33AM  Why 2017 Was a Year to Remember for Gilead Sciences, Inc. Motley Fool
08:00AM  Dynavax To Launch Hepatitis B Vaccine Is An Acquisition Coming? Investor's Business Daily
Jan-04-18 12:19PM  Why Juno Therapeutics Stock Cooled Off in December Motley Fool
07:30AM  Here's Why Unknown Orgenesis (ORGS) Shares Could Deliver 1100% Near Term Returns ACCESSWIRE
06:03AM  18 Reasons I Like Biotech Stocks in 2018 Motley Fool
Jan-03-18 01:45PM  Why This Is the Perfect Level to Buy Celgene Corporation Stock InvestorPlace
09:37AM  Gilead Will Be a Buy at 'Some Point.' Some Point Isn't Now. Barrons.com
Jan-02-18 04:22PM  Here's How bluebird bio, Inc. Crushed It in 2017 Motley Fool
02:41PM  Why 2017 Was a Year to Remember for Juno Therapeutics Motley Fool
Jan-01-18 12:01PM  The Intrinsic Value Of Gilead Science Forbes
Dec-30-17 07:00AM  3 Biggest Breakthroughs in Cancer Treatment in 2017 Motley Fool
Dec-29-17 07:56AM  Intercept (ICPT) Stock Loses Sheen in 2017: What Lies Ahead? Zacks
07:00AM  Why Gilead Sciences Stock Should Be Avoided in 2018 Motley Fool
Dec-27-17 01:06PM  Cannabis and tech stocks will be the 2018 leaders: NYSE trader Yahoo Finance Video
09:05AM  Estimating The Intrinsic Value Of Gilead Sciences Inc (NASDAQ:GILD) Simply Wall St.
Dec-22-17 06:00AM  GE's Stock Investors Should Brace for More Pain Investopedia
05:56AM  Is A Company You Own Making A Dumb Acquisition Harvest Exchange
Dec-21-17 06:55PM  The Top 8 Market-Moving Healthcare Stories of 2017 Motley Fool
04:01PM  Gilead Sciences to Present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8 Business Wire
01:37PM  Be Extremely Careful With Valeant Pharmaceuticals Intl Inc Stock Price InvestorPlace
10:00AM  Gilead: Maybe 2018 Won't Be Its Year Either Barrons.com
Dec-20-17 12:23PM  Credit Suisse: Street Expectations 'Too High' For Gilead's Hep C Therapy Benzinga
10:30AM  Analysts Recommendations for Gilead Sciences in December 2017 Market Realist
09:50AM  A Tale of Two Biotechs: Why Biogen Beats Gilead Barrons.com
09:01AM  Analysts Expectations for Gilead Sciences Market Realist
07:31AM  Gileads Other Products in 3Q17 Market Realist
Dec-19-17 02:05PM  Why These Biotech Stocks Could Be Taken Over In 2018 Investor's Business Daily
11:01AM  Gilead Sciences, Inc. : GILD-US: Dividend Analysis : December 15th, 2017 (record date) : By the numbers : December 19, 2017 Capital Cube
10:31AM  Harvoni Sales Fall in 3Q17 Market Realist
09:02AM  Gileads Hepatitis C Portfolio in 3Q17 Market Realist
08:01AM  3 Questions Keeping Juno Therapeutics' Investors Up at Night Motley Fool
07:33AM  Gileads HIV and Hepatitis B Portfolio in 3Q17 Market Realist
Dec-18-17 04:55PM  Changes in Gileads Revenue Trends in 3Q17 Market Realist
04:26PM  Why No Large-Cap Biotech Franchise Is Safe From Threats In 2018 Investor's Business Daily
03:21PM  Gilead Sciences Valuation in December 2017 Market Realist
Dec-17-17 11:33AM  3 Top Stocks That Are Cash Cows Motley Fool
Dec-16-17 08:37AM  Even in This Rich Market, Gilead Sciences, Inc. Is Offering Investors Value Motley Fool
Dec-15-17 07:00PM  Galapagos Cozies Up Closer to Gilead Sciences Motley Fool
04:28PM  CAR T Stocks in Focus with ASH 2017 Meet: GILD, JUNO & More Zacks
04:10PM  Gilead & Galapagos: Let's Just Be Friends Barrons.com
02:43PM  Novel Cancer Drug Gets Stymied by Medicare Rigid Billing System Bloomberg
Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company??s products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis C virus and hepatitis B virus; hematology/oncology; cardiovascular; and inflammation/respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., Galapagos NV., and Spring Bank Pharmaceuticals, Inc. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Meyers James REVP Worldwide Commercial OpsJan 16Option Exercise21.58100,0002,157,500102,715Jan 18 06:31 PM
Meyers James REVP Worldwide Commercial OpsJan 16Sale80.24100,0008,024,3642,715Jan 18 06:31 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 11Option Exercise36.0225,875932,06275,488Jan 16 05:42 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 11Sale79.0030,0002,370,00045,488Jan 16 05:42 PM
MARTIN JOHN CExecutive ChairmanJan 02Option Exercise23.6050,0001,180,0003,046,766Jan 04 07:54 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 02Option Exercise24.918,625214,80664,613Jan 04 08:05 PM
MARTIN JOHN CExecutive ChairmanJan 02Sale73.6250,0003,681,2352,996,766Jan 04 07:54 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 02Sale73.8715,0001,108,01949,613Jan 04 08:05 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffDec 01Option Exercise24.918,625214,80670,988Dec 05 06:17 PM
MARTIN JOHN CExecutive ChairmanDec 01Option Exercise21.5873,3331,582,1593,070,099Dec 05 07:49 PM
MARTIN JOHN CExecutive ChairmanDec 01Sale74.9873,3335,498,3852,996,766Dec 05 07:49 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffDec 01Sale74.6415,0001,119,55255,988Dec 05 06:17 PM
MILLIGAN JOHN FPresident and CEONov 13Option Exercise21.58220,0004,746,5001,385,924Nov 15 03:19 PM
MILLIGAN JOHN FPresident and CEONov 13Sale72.88220,00016,034,6781,165,924Nov 15 03:19 PM
Meyers James REVP Worldwide Commercial OpsNov 05Option Exercise0.004,50007,215Nov 07 05:47 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 01Option Exercise24.918,625214,80677,363Nov 03 06:59 PM
MARTIN JOHN CExecutive ChairmanNov 01Option Exercise21.5873,3331,582,1593,070,099Nov 03 07:04 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 01Sale74.8215,0001,122,28562,363Nov 03 06:59 PM
MARTIN JOHN CExecutive ChairmanNov 01Sale75.1373,3335,509,6972,996,766Nov 03 07:04 PM
MARTIN JOHN CExecutive ChairmanOct 02Option Exercise21.5873,3331,582,1593,070,099Oct 04 07:19 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffOct 02Option Exercise24.9117,250429,61193,738Oct 04 07:26 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffOct 02Sale82.6525,0002,066,30768,738Oct 04 07:26 PM
MARTIN JOHN CExecutive ChairmanOct 02Sale82.5673,3336,054,3192,996,766Oct 04 07:19 PM
Washington Robin LEVP, CFOSep 07Option Exercise24.3033,750819,95643,352Sep 11 08:35 PM
Washington Robin LEVP, CFOSep 07Sale85.0018,0701,535,950103,477Sep 11 08:35 PM
Washington Robin LEVP, CFOSep 07Sale85.0033,7502,868,7509,602Sep 11 08:35 PM
MARTIN JOHN CExecutive ChairmanSep 01Option Exercise21.5873,3331,582,1593,070,099Sep 06 08:23 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 01Option Exercise24.9117,250429,611101,488Sep 06 06:56 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 01Sale83.0525,0002,076,18876,488Sep 06 06:56 PM
MARTIN JOHN CExecutive ChairmanSep 01Sale83.1173,3336,094,9922,996,766Sep 06 08:23 PM
Meyers James REVP Worldwide Commercial OpsAug 31Option Exercise21.0060,0001,260,00062,715Sep 05 05:31 PM
Meyers James REVP Worldwide Commercial OpsAug 31Sale83.1960,0004,991,2902,715Sep 05 05:31 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 30Option Exercise25.9243,1251,117,815134,238Sep 01 05:15 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 30Sale79.0050,0003,950,00084,238Sep 01 05:15 PM
YOUNG KEVINChief Operating OfficerAug 10Option Exercise0.0091007,141Aug 14 06:57 PM
Meyers James REVP Worldwide Commercial OpsAug 10Option Exercise0.0082003,535Aug 14 06:53 PM
MARTIN JOHN CExecutive ChairmanAug 01Option Exercise21.5873,3331,582,1593,199,969Aug 03 06:55 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 01Option Exercise26.998,625232,789106,113Aug 03 06:58 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 01Sale75.8815,0001,138,19091,113Aug 03 06:58 PM
MARTIN JOHN CExecutive ChairmanAug 01Sale75.8673,3335,562,7773,126,636Aug 03 06:55 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 21Option Exercise26.9934,500931,155137,488Jul 25 06:53 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 21Sale74.0040,0002,960,00097,488Jul 25 06:53 PM
MARTIN JOHN CExecutive ChairmanJul 03Option Exercise21.5873,3331,582,1593,199,969Jul 06 06:38 PM
MARTIN JOHN CExecutive ChairmanJul 03Sale71.0073,3335,206,8923,126,636Jul 06 06:38 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 03Sale71.065,000355,295102,988Jul 06 06:27 PM
MARTIN JOHN CExecutive ChairmanJun 01Option Exercise21.5873,3331,582,1593,273,302Jun 05 06:26 PM
MARTIN JOHN CExecutive ChairmanJun 01Sale65.2473,3334,784,5313,199,969Jun 05 06:26 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJun 01Sale65.025,000325,114107,988Jun 05 06:15 PM
Cogan John FrancisDirectorMay 09Option Exercise20.7115,000310,57562,562May 11 06:14 PM
Cogan John FrancisDirectorMay 09Sale67.259,943668,66752,619May 11 06:14 PM
MARTIN JOHN CExecutive ChairmanMay 01Option Exercise21.5873,3331,582,1593,199,969May 03 05:42 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffMay 01Sale68.315,000341,529112,988May 03 05:41 PM
MARTIN JOHN CExecutive ChairmanMay 01Sale68.3173,3335,009,4293,126,636May 03 05:42 PM
MARTIN JOHN CExecutive ChairmanApr 03Option Exercise21.5873,3331,582,1593,199,969Apr 05 05:29 PM
MARTIN JOHN CExecutive ChairmanApr 03Sale67.1873,3334,926,2873,126,636Apr 05 05:29 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffMar 30Sale67.485,000337,392117,988Apr 03 06:23 PM
MARTIN JOHN CExecutive ChairmanMar 01Option Exercise21.5873,3331,582,1593,199,969Mar 03 06:29 PM
MOORE NICHOLAS GDirectorMar 01Option Exercise0.00173012,055Mar 03 06:03 PM
MARTIN JOHN CExecutive ChairmanMar 01Sale70.3873,3335,161,2063,126,636Mar 03 06:29 PM
WILSON GAYLE EDirectorFeb 23Option Exercise20.7133,350690,512140,836Feb 27 06:29 PM
MILLIGAN JOHN FPresident and CEOFeb 23Option Exercise21.58100,0002,157,5001,165,924Feb 27 06:13 PM
WILSON GAYLE EDirectorFeb 23Sale69.3020,3651,411,374120,471Feb 27 06:29 PM
YOUNG KEVINChief Operating OfficerFeb 10Option Exercise0.0090802,883Feb 14 12:53 PM
MARTIN JOHN CExecutive ChairmanFeb 01Option Exercise21.5873,3331,582,1593,204,429Feb 03 05:25 PM
YOUNG KEVINChief Operating OfficerFeb 01Option Exercise0.0062002,190Feb 03 05:32 PM
MARTIN JOHN CExecutive ChairmanFeb 01Sale72.5773,3335,322,0693,131,096Feb 03 05:25 PM